A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Read more about A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Read more about Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Read more about A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer Read more about Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Read more about Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Community Central Line Infection Prevention Trial Read more about Community Central Line Infection Prevention Trial
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors Read more about An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) Read more about Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Read more about Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfille Read more about An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfille